Angiotensin 1 Human

Angiotensin II is a potent direct vasoconstrictor, causing arteries and veins to constrict, so leading to an increase in blood pressure. Angiotensin also potentiates the release of norepinephrine by a direct action on postganglionic sympathetic fibers.

Angiotensin II is a potent direct vasoconstrictor, causing arteries and veins to constrict, so leading to an increase in blood pressure.

Angiotensin I (human, mouse, rat) is the precursor to the vasoconstrictor peptide angiotensin II, cleaved by the angiotensin-converting enzyme (ACE). This peptide hormone causes vasoconstriction and increases blood pressure as part of the renin–angiotensin system, also stimulating aldosterone release from the adrenal cortex to promote sodium retention by the kidneys.

Angiotensinogen (1-14), human acetate is a fragment of angiotensinogen which is a passive substrate of the renin-angiotensin system.

Losartan Carboxylic Acid (E-3174), a potent AT1 antagonist (Kis: 0.57 nM, rat; 0.67 nM, human), produces a depressor response and vasodilatation. As a metabolite of losartan, it is more potent than losartan in blocking angiotensin II-induced responses in vascular smooth muscle cells.

4-hydroxy Valsartan is a major metabolite of the angiotensin II type 1 (AT1) receptor antagonist valsartan . It reduces platelet aggregation induced by epinephrine and collagen but not ADP in human whole blood.

AT2R antagonist 1 is a highly selective and potent AT2R (angiotensin II AT2 receptor) ligand.AT2R antagonist 1 has a high affinity for AT2R affinity (Ki: 29 nM).AT2R antagonist 1 inhibits common drug metabolizing CYP enzymes and has high stability in human, rat, and mouse liver microsomes.AT2R antagonist 1 has a high affinity for AT2R affinity (Ki: 29 nM).AT2R antagonist 1 has a high affinity for AT2R affinity (Ki: 29 nM). It has high stability in human, rat and mouse liver microsomes.

Angiotensin II human TFA is a potent vasoconstrictor in the renin-angiotensin system that regulates blood pressure through interactions with AT1R and AT2R receptors. It activates sympathetic nerve activity, promotes aldosterone synthesis and renal function, induces proliferation of vascular smooth muscle cells, and enhances type I and III collagen production in fibroblasts, leading to vascular and myocardial thickening and fibrosis. It also triggers apoptosis and promotes capillary formation, making it suitable for establishing models of cardiac hypertrophy, hypertension, and abdominal aortic aneurysm.

Bebtelovimab (LY-CoV1404) is a neutralizing, fully human IgG1 monoclonal antibody targeting the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. This product binds specifically to a highly conserved epitope on the RBD, blocking the interaction between the spike protein and the human angiotensin-converting enzyme 2 (ACE2) receptor. Bebtelovimab exhibits potent and broad neutralizing activity against various SARS-CoV-2 variants, including Omicron (BA.1/BA.2), Delta, and other earlier strains. In clinical settings, it is utilized to reduce the risk of severe disease progression in high-risk ambulatory patients, such as solid organ transplant recipients.

Safflor Yellow B mitigates angiotensin II-induced injury in human umbilical vein cells by modulating Bcl-2/p22(phox) expression and demonstrates neuroprotective effects [1].

Zofenoprilat, an angiotensin-converting enzyme (ACE; IC50 = 8 nM for rabbit lung enzyme) inhibitor and the active metabolite of the prodrug zofenopril, effectively counters angiotensin I- or bradykinin-induced contractions in isolated guinea pig ileum (EC50s = 3 and 1 nM, respectively). At a concentration of 10 nM, Zofenoprilat not only diminishes basal endothelin-1 secretion and nitric oxide (NO) production but also safeguards against TNF-α-stimulated increases in reactive oxygen species (ROS) and reductions in glutathione (GSH) levels within human umbilical vein endothelial cells (HUVECs). Furthermore, at 10 µM, it delivers protection to primary human cardiac microvascular endothelial cells from doxorubicin-induced toxicity and enhances hydrogen sulfide (H2S) production, along with the adhesion, migration, and proliferation of HUVECs. Additionally, Zofenoprilat (400 µM) mitigates end diastolic pressure and lactate dehydrogenase (LDH) release, demonstrating therapeutic potential in a Langendorff isolated perfused rat heart model of ischemia-reperfusion injury.

Angiotensin II human acetate is a key vasoconstrictor peptide in the renin-angiotensin system. It regulates blood pressure by binding to AT1R and AT2R receptors, stimulates the sympathetic nervous system, promotes aldosterone synthesis and renal function, induces vascular smooth muscle cell proliferation and collagen synthesis, leading to vascular and myocardial hypertrophy and fibrosis, while also promoting apoptosis and endothelial capillary formation. It is commonly used to induce hypertension and cardiac hypertrophy models.

Angiotensin II human-13C6,15N trifluoroacetic acid is a version of angiotensin II human that is labeled with carbon-13 and nitrogen-15, in trifluoroacetic acid form. Angiotensin II human trifluoroacetic acid (T74142) acts as a vasoconstrictor and is the principal bioactive peptide in the renin-angiotensin system. This compound plays a crucial role in regulating blood pressure in the human body, primarily through interactions between angiotensin II and the G protein-coupled receptors (GPCR), specifically the angiotensin II type 1 receptor (AT1R) and type 2 receptor (AT2R). Additionally, Angiotensin II human (Angiotensin II) trifluoroacetic acid enhances sympathetic nervous stimulation, increases aldosterone biosynthesis, and affects renal function.

Losartan Carboxylic Acid (Standard) is a reference standard for research and analysis in studies involving Losartan Carboxylic Acid. Losartan Carboxylic Acid (E-3174) a potent AT1 antagonist (Kis: 0.57 nM, rat; 0.67 nM, human), producing a depressor response and vasodilatation. Losartan Carboxylic Acid , a metabolite of losartan, is more potent than losartan in blocking the angiotensin II-induced responses in vascular smooth muscle cells.

C-Type Natriuretic Peptide (CNP) (1-22), human, is the 1-22 fragment of the parent C-Type Natriuretic Peptide.

Angiotensinogen (1-14), human, also known as angiotensin precursor, is a serum globulin synthesized by the liver that is hydrolyzed by renin to form angiotensin I,

Angiotensinogen (1-14), human TFA is a fragment of the renin substrate angiotensinogen, which is a precursor for all angiotensin peptides.